Movement Disorders
News
Parkinson’s Foundation Hosting Conference on Use of Medical Marijuana
Thursday, February 14, 2019—On March 6-7, in Denver, CO, The Parkinson’s Foundation will host its first conference focused on the use of medical marijuana as potential therapy for patients with Par…
Wearable Device Provides Data for Treatment of Parkinson’s Disease
Wednesday, February 06, 2019—A study to be published in the Journal of Parkinson’s Disease and made available in prepress form shows that a wearable device (Personal KinetiGraph, Global Ki…
Novel Small Molecule PBT434 Receives Orphan Drug Designation for Treatment of Multiple System Atrophy
Friday, February 01, 2019—The Food and Drug Administration (FDA) has granted orphan drug designation for the molecule PBT434 (Prana Biotechnology LTD,Melbourne, Australia) as a potential treatment for …
First Patient Treated in Phase 3 Study of Ampreloxetine for Neurogenic Orthostatic Hypotension
Tuesday, January 29, 2019—The first patient has been dosed in a registrational phase 3 study (NCT03750552) of ampreloxetine (TD955; Theravance Biopharma, South San Francisco, CA) for treating symptomat…
Continuous Delivery of Levodopa May Decrease Motor Complications of OFF Time
Monday, January 28, 2019—A small open-label study, published in the journal Movement Disorders, compared the efficacy and pharmacokinetics of continuously administered oral levodopa/carbidopa (si…
Valbenazine Reduces Involuntary Movements in Patients with Mood Disorders
Friday, January 18, 2019—A post-hoc analysis of data from a clinical trial of valbenazine (Ingrezza; Neurocrine Biosciences, Inc., San Diego, CA) has been published in the Journal of Affective Di…
First Patients Enrolled in Trial of Wearable Neurostimulation Device for Treating Essential Tremor
Thursday, January 17, 2019—The Pacific Movement Disorders Center at Pacific Neuroscience Institute announced that the first patients have been enrolled into a trial of a wearable, external, and wireless…
Breakthrough Device Designation Granted to Brain-Monitoring Technology
Wednesday, January 09, 2019—The Food and Drug Administration has granted breakthrough device designation to a brain health monitoring technology (Neurametrix; San Francisco, CA). The approved use is moni…
